Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on Convoy Therapeutics, Inc.

NEW YORK, NY--(Marketwired - Jun 19, 2013) - Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview^® (EIO) on Convoy Therapeutics, Inc. The full 52-page report is available on Crystal Research Associates' website at www.crystalra.com.

Convoy Therapeutics, Inc. ("Convoy" or "the Company") is a late-stage, closely held, biotechnology company developing a next-generation drug delivery technology. Convoy's innovative Skin-Penetrating-And-Cell-Entering (SPACE) Peptide Technology uses a family of proprietary peptide sequences to transport topical drug and cosmetic compounds into the skin. A key competitive advantage of the SPACE technology is that it can be used to administer both small and large molecules. Many biologic drugs and therapeutic proteins, among other macromolecules, cannot be effectively delivered through the skin with current technologies due to the size of the active molecule. The SPACE Peptide not only facilitates skin penetration of large molecules but has also been shown to retain small compounds in the skin, potentiating a longer-lasting treatment effect. The technology is non-invasive and has been found to be non-toxic.

Convoy's pipeline includes using the SPACE platform to reformulate a well-known oral and injectable therapeutic, cyclosporine A, into a topical treatment for psoriasis called CycloPsorb™, as well as creating a topical hyaluronic acid cosmetic compound to reduce fine lines/wrinkles as a supplement to dermal filler and Botox^® injections.

Be the first to hear about Crystal Research's new report releases and upcoming media coverage. Follow us on Twitter at http://twitter.com/crystalresearch or visit http://crystalra.com/blog/ for more coverage.

About Crystal Research Associates, LLC

Crystal Research Associates, LLC (www.crystalra.com) is an independent research firm that has provided institutional-quality research on small- and mid-cap companies for the past decade. The firm is led by veteran Wall Street sell-side analyst Jeffrey Kraws, who is well known by the international financial media for his years of work on Wall Street as well as for providing consistent award-winning analyses and developing long-term relationships on both the buy-side and sell-side. He has been consistently ranked on Wall Street among the Top Ten Analysts for pharmaceutical stock performance in the world for almost two decades as well as ranked as the Number One Stock Picker in the world for pharmaceuticals by Starmine and for estimates from Zacks. Additionally, Mr. Kraws has been 5-Star ranked for top biotechnology stock performance by Starmine.

Crystal Research Associates' unique and novel product, the Executive Informational Overview^® (EIO), is free of investment ratings, target prices, and forward-looking financial models. The EIO presents a crystal clear, detailed report on a company (public or private) in a manner that is easily understood by the Wall Street financial community. The EIO details a company's product/technology/service offerings, market size(s), key intellectual property, leadership, growth strategy, competition, risks, financial statements, key events, and other such fundamental information. Crystal Research Associates has offices in New York City and West Palm Beach. Crystal Research Associates has been compensated by the Company in cash of forty-two thousand, five hundred U.S. dollars and forty-two thousand, five hundred warrants.

Forward-Looking Safe Harbor Statement

Statements in this news release regarding future financial and operating results, potential applications of the Company's technology, opportunities for the Company, and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including limited operating history, need for future capital, and economic conditions generally. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in the Company's periodic news and reports.

These statements, and other forward-looking statements, are not guarantees of future performance and involve risks and uncertainties. Crystal Research Associates assumes no obligation to update any of the forward-looking statements in this release.